• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

US FDA Orphan Drug Designation

Background

As our understanding of the underlying biology of ALS has improved, multiple experimental treatment approaches have been identified. Currently, there are numerous interventional drug trials testing a diverse set of targets using multiple drug approaches (for example, small molecules, antibodies, stem cells, and gene interface/silencing technologies).

Drug regulators have also set up programs to provide special incentives for companies to develop drugs and biologicals for rare diseases that have a small market (fewer than 200,000 people in the United States, as with ALS). One such program is the orphan drug designation (or sometimes “orphan status”) administered by the US Food and Drug Administration (FDA).

Created in 1983, this program provides financial incentives and research subsidies, such as a partial tax credit for clinical trial expenditures, waived user fees, and eligibility for market exclusivity for the drug. The European Medicines Agency (EMA) of the European Union has a similar program and defines a drug as “orphan” for a rare disease affecting fewer than 5 in 10,000 people.

Benefit for patients

The National Organization for Rare Disorders, along with many other organizations, led the lobbying efforts for the passage and creation of this program. Companies will typically shy away from developing drugs for a rare disease area because of financial considerations, limited profit margins, and the scientific, ethical, and operational complexities of conducting clinical research in small niche patient populations. This program motivates, supports, and incentivizes drug companies to invest their research and development capital (both scientific and financial), with the hope that more medical breakthroughs will be made available for patients with rare diseases than would otherwise have been achieved.

Benefit for companies and sponsors

Companies benefit from this program because it gives them exclusive marketing and development rights and allows them to recover part of the cost of researching and developing the drug. In addition to cost reductions, the FDA provides streamlined regulatory processes and guidance for drugs with this designation. Investors in pharmaceutical companies also often view orphan designation as a signal of higher company value, which brings in more of the capital needed for drug discovery programs.

What orphan drug designation means and does not mean

While orphan drug designation can be an important milestone for a drug company, orphan drugs, like non-orphan drugs, are still required to show safety and efficacy before approval for use as a therapeutic. Orphan drug designations are typically given early in development, and orphan drugs must still follow the proper clinical development and regulatory process.

Orphan drug designation should also not be confused with other regulatory designations, such as fast-track designation. Fast-track designation does not provide drug companies with any explicit financial benefits for developing a drug. However, it does provide more frequent meetings with the FDA, as well as an expedited review when a company submits an application to bring a new drug to market.

Recommendation

The Scientific Advisory Council (SAC) hopes that drug companies will take advantage of incentives and expedited pathways set up by regulatory agencies, such as the orphan drug designation, to discover and rigorously test new treatments for people living with ALS/MND.

International Alliance of ALS/MND Associations
July 2020


The original language of communication is English, and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • Anderson Custodio Pinto, Brazil

    Anderson Custodio Pinto, Brazil

  • Francisco Perez Palop, Spain

    Francisco Perez Palop, Spain

  • Brian Lovell, Australia

    Brian Lovell, Australia

  • Margreth Burger-Saile, Switzerland

    Margreth Burger-Saile, Switzerland

  • Bjarne Hytjanstorp, Norway

    Bjarne Hytjanstorp, Norway

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Jean Waters, UK

    Jean Waters, UK

  • Susan Keldani, USA

    Susan Keldani, USA

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Yannick Richard, Canada

    Yannick Richard, Canada
    yannickrichard

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Marcelo Farinelli, Brazil

    Marcelo Farinelli, Brazil

  • Alberto Baez Murillo, Colombia

    Alberto Baez Murillo, Colombia

  • Jack Buzby, USA

    Jack Buzby, USA

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Mauril Bélanger, Canada

    Mauril Bélanger, Canada

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Animesh Kumar, India

    Animesh Kumar, India

  • Steve

    Steve

  • John Dinon, Australia

    John Dinon, Australia

  • Ada Garrido Benavidez, Mexico

    Ada Garrido Benavidez, Mexico

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

  • Glen Victor Peters, Australia

    Glen Victor Peters, Australia

  • Charlie Dourney, USA

    Charlie Dourney, USA

  • Steven Spencer, New Zealand

    Steven Spencer, New Zealand

  • Liam Dwyer, England

    Liam Dwyer, England

  • João Marcos Andrietta, Brazil

    João Marcos Andrietta, Brazil

  • Stephanie Christiansen Hall, Canada

    Stephanie Christiansen Hall, Canada

  • Elkin Ramiro Gaviria Muñoz, Colombia

    Elkin Ramiro Gaviria Muñoz, Colombia

  • Ana Lilia Rodriguez, Mexico

    Ana Lilia Rodriguez, Mexico

  • Horacio Fritzer, Argentina

    Horacio Fritzer, Argentina

  • Jo Knowlton, Scotland

    Jo Knowlton, Scotland

  • Ismail Gokcek, Turkey

    Ismail Gokcek, Turkey
    ismail_gokcek_alsmnd_tr

  • Cath Muir, UK

    Cath Muir, UK
    Cath

  • Hollister

    Hollister
    hollister

  • Alejandro Aquino, Argentina

    Alejandro Aquino, Argentina

  • Hans Dieter Olszewski, Germany

    Hans Dieter Olszewski, Germany

  • Lucy Lintott, Scotland

    Lucy Lintott, Scotland

  • Maria Santos Garcia Tellez, Mexico

    Maria Santos Garcia Tellez, Mexico

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Chirag Walia, India

    Chirag Walia, India
    ChiragWalia

  • Calum Ferguson, Scotland

    Calum Ferguson, Scotland

  • Norm MacIsaac, Canada

    Norm MacIsaac, Canada

  • Camilla Heiberg Freiberg, Denmark

    Camilla Heiberg Freiberg, Denmark

  • Eddy Lefrancois, Canada

    Eddy Lefrancois, Canada

  • Robbie Caliste, UK

    Robbie Caliste, UK

  • Colm Francis Davis, Ireland

    Colm Francis Davis, Ireland

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login